Cita APA

Chen, C., Luo, X., Tang, W., Geng, H., Martínez-Pérez, J., Price, T., . . . Zhang, Y. (2024). Regorafenib combined with immune checkpoint inhibitors versus regorafenib monotherapy as a late-line treatment for metastatic colorectal cancer: A single-center, retrospective cohort study.

Citación estilo Chicago

Chen, Can, Xi Luo, Wenhua Tang, Haofei Geng, Julia Martínez-Pérez, Timothy Price, Lili Kang, Honglian Lu, y Yanling Zhang. Regorafenib Combined With Immune Checkpoint Inhibitors Versus Regorafenib Monotherapy As a Late-line Treatment for Metastatic Colorectal Cancer: A Single-center, Retrospective Cohort Study. 2024.

Cita MLA

Chen, Can, et al. Regorafenib Combined With Immune Checkpoint Inhibitors Versus Regorafenib Monotherapy As a Late-line Treatment for Metastatic Colorectal Cancer: A Single-center, Retrospective Cohort Study. 2024.